View ValuationSolvonis Therapeutics 향후 성장Future 기준 점검 0/6Solvonis Therapeutics의 수익이 할 전망입니다. 주당 순이익은 성장 연간 31.5%만큼 감소할 것으로 예상됩니다.핵심 정보9.2%이익 성장률31.50%EPS 성장률Biotechs 이익 성장25.1%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트09 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 22Solvonis Therapeutics Announces Positive Bridging Data Supporting Planned U.S. 505(b)(2) Pathway Towards Phase 2b Clinical Trial of SVN-002Solvonis Therapeutics plc announced positive pharmacokinetic (PK) data from the preclinical bridging study for its SVN-002 development programme. SVN-002 is Solvonis' proprietary esketamine oral thin-film (OTF) formulation being developed for moderate-to-severe Alcohol Use Disorder (AUD) in the United States. It is designed for supervised, clinic-administered sublingual-buccal dosing. The programme also incorporates a structured alcohol education component, intended for future remote digital access by patients. The programme is being advanced under a planned U.S. Food and Drug Administration (FDA) 505(b)(2) regulatory pathway referencing the FDA-approved intranasal esketamine product, Spravato®. The nonclinical study was designed to assess whether the intended combined sublingual-buccal administration of SVN-002 could generate systemic esketamine exposure supportive of a scientific bridge to the approved intranasal esketamine reference product. At the same nominal dose level, combined sublingual-buccal administration of SVN-002 produced rapid systemic exposure to parent esketamine. Exposure levels for parent esketamine and the key measured metabolites, noresketamine and hydroxynoresketamine, were within the range observed for the intranasal esketamine comparator arm, providing important translational support for the planned scientific bridge. At the December 2024 Type B pre-IND meeting held with the FDA by Awakn Life Sciences, prior to the asset's acquisition by Solvonis, FDA identified systemic exposure to esketamine and relevant metabolite exposure as key considerations for the initial Investigational New Drug (IND) package. Solvonis believes these newly generated data provide important translational support in relation to the FDA-identified exposure considerations and strengthen the planned initial IND package for SVN-002. Following these positive results, Solvonis will seek further FDA feedback on the scope and scale of the remaining nonclinical toxicology work required for the initial IND submission. Subject to FDA feedback and successful completion of this targeted toxicology package, Solvonis plans to submit an IND to support the initiation of a Phase 2b clinical trial of SVN-002 in patients with moderate-to-severe AUD in the United States. AUD represents a major and underserved U.S. market opportunity characterised by limited pharmacological innovation. According to the 2024 U.S. National Survey on Drug Use and Health, approximately 27,900,000 people aged 12 and older in the U.S. had Alcohol Use Disorder in the past year. Solvonis estimates that approximately 15,000,000 U.S. adults fall within the programme's target moderate-to-severe AUD population. Spravato® provides a relevant commercial reference point for supervised, clinic-administered esketamine treatment models. Johnson & Johnson reported worldwide Spravato® sales of approximately USD 1,700 million in 2025 for depression-related indications. Solvonis estimates that SVN-002's target U.S. moderate-to-severe AUD population is approximately five times larger than the estimated U.S. treatment-resistant depression comparator population of approximately 2,800,000 people. The planned 505(b)(2) pathway is central to the capital efficiency of the SVN-002 development strategy. A successful 505(b)(2) route may allow Solvonis to rely, in part, on the FDA's prior findings of safety and/or effectiveness for the approved intranasal esketamine reference product, provided a suitable scientific bridge is established. Solvonis intends to build the SVN-002 package using existing third-party preclinical data, in-licensed Phase 1 clinical data, and targeted SVN-002 bridging and toxicology studies, rather than duplicating a full conventional de novo development package. The Company believes this approach has the potential to reduce development expenditure and support a more capital-efficient route towards Phase 2b. The pharmacokinetic profile observed in this study is very encouraging. Combined sublingual-buccal administration produced rapid systemic exposure to parent esketamine and supports the core rationale for SVN-002 as a transmucosal thin-film product. These results provide important translational evidence for the planned U.S. regulatory pathway and support SVN-002's continued development as a supervised, clinic-administered treatment candidate for AUD.공고 • May 28Solvonis Therapeutics plc, Annual General Meeting, Jun 19, 2026Solvonis Therapeutics plc, Annual General Meeting, Jun 19, 2026. Location: the offices of orana corporate llp, eccleston yards, 25 eccleston place, sw1w 9nf, london United Kingdom공고 • Mar 12Solvonis Therapeutics plc Announces Selection of SVN-114 as Lead Candidate from its Proprietary SVN-SDN-14 Discovery ProgrammeSolvonis Therapeutics plc announced the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery programme targeting Post-Traumatic Stress Disorder ("PTSD"), a condition affecting more than 20 million people worldwide for which effective pharmacological treatment options remain limited. The selection follows compelling pharmacology results from preclinical studies conducted by Evotec SE, in which SVN-114 demonstrated balanced modulation of serotonin ("SERT"), dopamine ("DAT") and noradrenaline ("NET"), key brain chemicals involved in mood, emotion and social behaviour. Following review of the pharmacology data, the Company's Scientific Advisory Committee, led by Professor David Nutt, agreed to designate SVN-114 as the programme's lead candidate, marking an important milestone for Solvonis' proprietary CNS discovery platform. Mechanism designed to support therapeutic engagement: The SVN-SDN-14 series is a class of serotonin ("SERT"), dopamine ("DAT") and noradrenaline ("NET") modulators designed to enhance pro-social behaviour and improve therapeutic outcomes for people living with PTSD. By modulating neurochemical pathways associated with trust, empathy and social bonding, compounds in this series, including SVN-114, are intended to help patients rebuild interpersonal relationships and engage more effectively in therapy. Novel chemistry supported by international patent applications: SVN-114 originates from a proprietary chemical series discovered through Solvonis' internal research programme. Composition-of-matter patent applications have been filed internationally covering both the compound class and its pharmaceutical applications.공고 • Jan 07+ 1 more updateSolvonis Therapeutics PLC Appoints Paul Rutherford Carter as Director, Effective October 27, 2025Solvonis Therapeutics PLC has appointed Paul Rutherford Carter as a director. The appointment was effective on October 27, 2025.공고 • Oct 28Solvonis Therapeutics plc Appoints Paul Carter as Non-Executive Director, Effective 27 October 2025Solvonis Therapeutics plc announced the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025. Paul Carter is a highly accomplished global biopharmaceutical leader with nearly three decades of senior executive experience spanning commercial, operational, and strategic leadership roles. He has built and scaled businesses across Europe, North America, and Asia, combining deep operational expertise with a proven record of driving transformational growth and delivering long-term shareholder value. Paul currently serves as Non-Executive Chair of Clinigen Group plc. He is also Chair of Memo Therapeutics AG and Chair of Kyowa Kirin International plc. In addition, Paul serves as Non-Executive Director at Immatics N.V. He previously held senior global roles including Executive Vice President and Chief Commercial Officer at Gilead Sciences Inc., where he oversaw international operations across 38 markets and delivered annual revenues exceeding USD 30 billion. His appointment strengthens the Solvonis Board as the Company continues to advance its differentiated CNS pipeline and execute its capital-efficient, licensing-first growth strategy across addiction, psychiatry, and neurology.공고 • Oct 17Solvonis Therapeutics plc has completed a Follow-on Equity Offering in the amount of £1.25 million.Solvonis Therapeutics plc has completed a Follow-on Equity Offering in the amount of £1.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 378,787,876 Price\Range: £0.0033 Transaction Features: Subsequent Direct Listing이익 및 매출 성장 예측OTCPK:SLVN.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028N/A-4N/AN/A112/31/2027N/A-4-5N/A212/31/2026N/A-4-4N/A212/31/2025N/A-6-3-3N/A9/30/2025N/A-4-2-2N/A6/30/2025N/A-3-2-2N/A3/31/2025N/A-2-1-1N/A12/31/2024N/A-1-1-1N/A9/30/20240-3-1-1N/A6/30/20240-2-1-1N/A3/31/20240-3-1-1N/A12/31/20231-3-1-1N/A9/30/20230-2-2-1N/A6/30/20230-3-2-1N/A3/31/20230-3-3-2N/A12/31/20221-3-3-2N/A6/30/20220-2-2-2N/A3/31/20220-2-1-1N/A12/31/20210-200N/A5/31/20211000N/A5/31/20200-100N/A5/31/20190-1N/A-1N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SLVN.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: SLVN.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: SLVN.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: SLVN.F 의 수익이 US 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: SLVN.F 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SLVN.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/13 07:00종가2026/07/10 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Solvonis Therapeutics plc는 1명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert SassoonWater Tower Research LLC
공고 • Jun 22Solvonis Therapeutics Announces Positive Bridging Data Supporting Planned U.S. 505(b)(2) Pathway Towards Phase 2b Clinical Trial of SVN-002Solvonis Therapeutics plc announced positive pharmacokinetic (PK) data from the preclinical bridging study for its SVN-002 development programme. SVN-002 is Solvonis' proprietary esketamine oral thin-film (OTF) formulation being developed for moderate-to-severe Alcohol Use Disorder (AUD) in the United States. It is designed for supervised, clinic-administered sublingual-buccal dosing. The programme also incorporates a structured alcohol education component, intended for future remote digital access by patients. The programme is being advanced under a planned U.S. Food and Drug Administration (FDA) 505(b)(2) regulatory pathway referencing the FDA-approved intranasal esketamine product, Spravato®. The nonclinical study was designed to assess whether the intended combined sublingual-buccal administration of SVN-002 could generate systemic esketamine exposure supportive of a scientific bridge to the approved intranasal esketamine reference product. At the same nominal dose level, combined sublingual-buccal administration of SVN-002 produced rapid systemic exposure to parent esketamine. Exposure levels for parent esketamine and the key measured metabolites, noresketamine and hydroxynoresketamine, were within the range observed for the intranasal esketamine comparator arm, providing important translational support for the planned scientific bridge. At the December 2024 Type B pre-IND meeting held with the FDA by Awakn Life Sciences, prior to the asset's acquisition by Solvonis, FDA identified systemic exposure to esketamine and relevant metabolite exposure as key considerations for the initial Investigational New Drug (IND) package. Solvonis believes these newly generated data provide important translational support in relation to the FDA-identified exposure considerations and strengthen the planned initial IND package for SVN-002. Following these positive results, Solvonis will seek further FDA feedback on the scope and scale of the remaining nonclinical toxicology work required for the initial IND submission. Subject to FDA feedback and successful completion of this targeted toxicology package, Solvonis plans to submit an IND to support the initiation of a Phase 2b clinical trial of SVN-002 in patients with moderate-to-severe AUD in the United States. AUD represents a major and underserved U.S. market opportunity characterised by limited pharmacological innovation. According to the 2024 U.S. National Survey on Drug Use and Health, approximately 27,900,000 people aged 12 and older in the U.S. had Alcohol Use Disorder in the past year. Solvonis estimates that approximately 15,000,000 U.S. adults fall within the programme's target moderate-to-severe AUD population. Spravato® provides a relevant commercial reference point for supervised, clinic-administered esketamine treatment models. Johnson & Johnson reported worldwide Spravato® sales of approximately USD 1,700 million in 2025 for depression-related indications. Solvonis estimates that SVN-002's target U.S. moderate-to-severe AUD population is approximately five times larger than the estimated U.S. treatment-resistant depression comparator population of approximately 2,800,000 people. The planned 505(b)(2) pathway is central to the capital efficiency of the SVN-002 development strategy. A successful 505(b)(2) route may allow Solvonis to rely, in part, on the FDA's prior findings of safety and/or effectiveness for the approved intranasal esketamine reference product, provided a suitable scientific bridge is established. Solvonis intends to build the SVN-002 package using existing third-party preclinical data, in-licensed Phase 1 clinical data, and targeted SVN-002 bridging and toxicology studies, rather than duplicating a full conventional de novo development package. The Company believes this approach has the potential to reduce development expenditure and support a more capital-efficient route towards Phase 2b. The pharmacokinetic profile observed in this study is very encouraging. Combined sublingual-buccal administration produced rapid systemic exposure to parent esketamine and supports the core rationale for SVN-002 as a transmucosal thin-film product. These results provide important translational evidence for the planned U.S. regulatory pathway and support SVN-002's continued development as a supervised, clinic-administered treatment candidate for AUD.
공고 • May 28Solvonis Therapeutics plc, Annual General Meeting, Jun 19, 2026Solvonis Therapeutics plc, Annual General Meeting, Jun 19, 2026. Location: the offices of orana corporate llp, eccleston yards, 25 eccleston place, sw1w 9nf, london United Kingdom
공고 • Mar 12Solvonis Therapeutics plc Announces Selection of SVN-114 as Lead Candidate from its Proprietary SVN-SDN-14 Discovery ProgrammeSolvonis Therapeutics plc announced the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery programme targeting Post-Traumatic Stress Disorder ("PTSD"), a condition affecting more than 20 million people worldwide for which effective pharmacological treatment options remain limited. The selection follows compelling pharmacology results from preclinical studies conducted by Evotec SE, in which SVN-114 demonstrated balanced modulation of serotonin ("SERT"), dopamine ("DAT") and noradrenaline ("NET"), key brain chemicals involved in mood, emotion and social behaviour. Following review of the pharmacology data, the Company's Scientific Advisory Committee, led by Professor David Nutt, agreed to designate SVN-114 as the programme's lead candidate, marking an important milestone for Solvonis' proprietary CNS discovery platform. Mechanism designed to support therapeutic engagement: The SVN-SDN-14 series is a class of serotonin ("SERT"), dopamine ("DAT") and noradrenaline ("NET") modulators designed to enhance pro-social behaviour and improve therapeutic outcomes for people living with PTSD. By modulating neurochemical pathways associated with trust, empathy and social bonding, compounds in this series, including SVN-114, are intended to help patients rebuild interpersonal relationships and engage more effectively in therapy. Novel chemistry supported by international patent applications: SVN-114 originates from a proprietary chemical series discovered through Solvonis' internal research programme. Composition-of-matter patent applications have been filed internationally covering both the compound class and its pharmaceutical applications.
공고 • Jan 07+ 1 more updateSolvonis Therapeutics PLC Appoints Paul Rutherford Carter as Director, Effective October 27, 2025Solvonis Therapeutics PLC has appointed Paul Rutherford Carter as a director. The appointment was effective on October 27, 2025.
공고 • Oct 28Solvonis Therapeutics plc Appoints Paul Carter as Non-Executive Director, Effective 27 October 2025Solvonis Therapeutics plc announced the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025. Paul Carter is a highly accomplished global biopharmaceutical leader with nearly three decades of senior executive experience spanning commercial, operational, and strategic leadership roles. He has built and scaled businesses across Europe, North America, and Asia, combining deep operational expertise with a proven record of driving transformational growth and delivering long-term shareholder value. Paul currently serves as Non-Executive Chair of Clinigen Group plc. He is also Chair of Memo Therapeutics AG and Chair of Kyowa Kirin International plc. In addition, Paul serves as Non-Executive Director at Immatics N.V. He previously held senior global roles including Executive Vice President and Chief Commercial Officer at Gilead Sciences Inc., where he oversaw international operations across 38 markets and delivered annual revenues exceeding USD 30 billion. His appointment strengthens the Solvonis Board as the Company continues to advance its differentiated CNS pipeline and execute its capital-efficient, licensing-first growth strategy across addiction, psychiatry, and neurology.
공고 • Oct 17Solvonis Therapeutics plc has completed a Follow-on Equity Offering in the amount of £1.25 million.Solvonis Therapeutics plc has completed a Follow-on Equity Offering in the amount of £1.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 378,787,876 Price\Range: £0.0033 Transaction Features: Subsequent Direct Listing